Ochsner Health Expands Liver Transplant Access Through Multidisciplinary Care Ari Cohen, MD, MBA

Published Date: 24 Oct 2026

Ochsner Health uses multidisciplinary clinics, living donor programs, and transplant innovations to address access challenges.

Read Full News

Latest News

Inside FIND-CKD: Can Finerenone Pair With Immunosuppression in GN? Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Brendon Neuen explains why finerenone's mechanism supports combining it with immunosuppressive therapy in glomerulonephritis.

Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Brendan Neuen breaks down the full FIND-CKD primary and secondary endpoint data, subgroup consistency, and safety signals.

You Don't Need to Be a GN Specialist to Identify Glomerular Disease Earlier George Vasquez-Rios, MD

George Vasquez-Rios, MD, explains the barriers in GN care that ASN's new compendium may address.

New ASN Compendium Tackles Fragmented GN Care, With Vasquez-Rios, MD George Vasquez-Rios, MD

A new ASN compendium curates scattered GN care guidance into one living resource, says nephrologist George Vasquez-Rios, MD

Uromodulin Drop Offers Clues to SGLT2 Kidney Protection, With Greco Malijan, MD Greco Malijan, MD

In EMPA-KIDNEY, empagliflozin cut urinary uromodulin 63% without signs of tubular injury, reshaping views on SGLT2 inhibitor mechanisms.

ASN Kidney Week 2026 Preview: 8 Late-Breakers We’ll Unpack With the Investigators

Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Latest News

Brendon Neuen explains why finerenone's mechanism supports combining it with immunosuppressive therapy in glomerulonephritis.

Brendan Neuen breaks down the full FIND-CKD primary and secondary endpoint data, subgroup consistency, and safety signals.

George Vasquez-Rios, MD, explains the barriers in GN care that ASN's new compendium may address.

A new ASN compendium curates scattered GN care guidance into one living resource, says nephrologist George Vasquez-Rios, MD

In EMPA-KIDNEY, empagliflozin cut urinary uromodulin 63% without signs of tubular injury, reshaping views on SGLT2 inhibitor mechanisms.

Preview 8 late-breaking studies and HCPLive's investigator interviews at ASN Kidney Week 2026, spanning IgAN, dialysis, transplantation, and CKD.

News All Time

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

Closing Gaps in IgA Nephropathy Diagnosis and Treatment, With Brad Rovin, MD Brad Rovin, MD

Brad Rovin, MD, discusses gaps in IgA nephropathy care, biopsy's expanding role, and how new B cell therapies are reshaping treatment.

What's Still Missing in IgA Nephropathy Care, With Brad Rovin, MD Brad Rovin, MD

Brad Rovin, MD, discusses persistent gaps in IgA nephropathy diagnosis and treatment, from RAS inhibition limits to the promise of B-cell-targeted therapies.

Bioengineered Vessel Increases Catheter-Free Time in Women on Dialysis Mohamad Hussain, MD, PhD

Mohamad Hussain, MD, PhD, discusses Phase 3 findings on Humacyte's bioengineered vessel and its potential role in vascular access for women on dialysis.

The HCPFive: Top News for Healthcare Providers from the Week of 08/09 HCPLive Editorial Staff

This week's highlight includes phase 3 trial results across dermatology, cardiology, and pulmonology, and a major conference preview.

Understanding the B-Cell Pathway in IgA Nephropathy, With Samir Parikh, MD Samir Parikh, MD

Samir Parikh, MD, on the B-cell pathway in IgA nephropathy, biomarker gaps, treatment sequencing, and the case for earlier detection.

4 Out of 5 Young Adults Show Early Cardiovascular-Kidney-Metabolic Risk Donald M. Lloyd-Jones, MD

Carotid ultrasound data reveal early arterial injury even at earlier CKM stages, says Donald Lloyd-Jones, MD, MS

How VISIONARY's Design Targets APRIL in IgA Nephropathy, With Dana Rizk, MD Dana Rizk, MD, Shikha Wadhwani, MD, MS, Brendon Neuen, MBBS, PhD

VISIONARY enrolled 510 high-risk IgAN patients globally. Learn how the trial's design and anti-APRIL mechanism were built to target disease at its root.

CKD Care Gaps for Incarcerated Patients, With Laura Maursetter, MD Laura Maursetter, MD

A nephrologist details gaps in tracking CKD screening, labs, and treatment in correctional care.

Closing the Gaps in CKD Screening, Transplant Access, and Education for Incarcerated Patients Laura Maursetter, MD

Laura J. Maursetter, MD, discusses the case for standardized kidney screening protocols, transplant access, and medical education reform for the correctional population.

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd Ali Mehdi, MD, MEd

Rethinking IgA Nephropathy Risk and Treatment, With Ali Mehdi, MD, MEd

Why CKD Treatment Should Start Earlier, Last Longer for Incarcerated Persons Laura Maursetter, MD

Laura J. Maursetter, MD, discusses why early kidney disease screening and continuity of care are especially critical for justice-involved patients.

Why IgA Nephropathy Risk Stratification Still Falls Short Ali Mehdi, MD, MEd

Cleveland Clinic's Ali Mehdi, MD, MEd, on the limits of current IgA nephropathy risk tools and where phenotyping could take treatment next.

For Incarcerated Patients, Kidney Care Can't Wait, With Laura Maursetter, MD Laura Maursetter, MD

A nephrologist outlines gaps in CKD tracking, medication access, and transplant standards across the carceral health system.

Recommended News For You

Laryngeal Transplant Helped a Cancer Patient Speak Again in Pioneering Study

WHO launches plan for free child cancer medicines

Exercise can counter detrimental effects of cancer treatment, review suggests

Alarm Over Pharma-China Link; Taking Screening to the People; Agriculture and Cancer

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

Recommended Articles For You

Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms  

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances 

CAR T + Ibrutinib in R/R Mantle Cell Lymphoma: Phase 2 TARMAC Study Insights 

Clinical Guidelines for Immune Effector Cell Therapy Monitoring 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.

2.

Researchers explore e-bikes for cancer recovery

3.

Acupuncture may alleviate nocturia in men treated for prostate cancer

4.

Watch for Psoriasis After Cancer Immunotherapy, Study Says

5.

Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.

1.

Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models

2.

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review

3.

Quality of Life Following Functional Hematopoietic Recovery

4.

Intracellular Nanobody Therapeutics: Mechanisms, Clinical Relevance, and Emerging Applications

5.

Beyond Driver Mutations: Context-Dependent Synthetic Lethality as the Next Frontier of Precision Oncology

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Emerging Concepts in Hematology

2.

Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

4.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

5.

Preventing Blood Clots: The Importance of Venous Thromboembolism Management

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot